Final week, Apellis Prescription drugs Inc APLS reported a fourth-quarter earnings lack of 29 cents per share, beating the consensus lack of 37 cents. Gross sales elevated 45.2% to $212.5 million, beating the consensus of $198.35 million.
JP Morgan maintains the Obese ranking with a worth forecast of $54.
Analyst Anupam Rama says Apellis’ lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset within the complement house, with alternatives throughout ophthalmology, hematology, neurology, and nephrology indications.
Additionally Learn: Syfovre’s Aggressive Edge Highlights Brilliant Future For Apellis Prescription drugs, Analyst Initiates With Bullish Pitch
The corporate generated Syfovre gross sales of $167.8 million and $611.9 million for the fourth quarter and full yr 2024, respectively.
Delivered roughly 94,000 Syfovre doses to doctor practices within the fourth quarter, together with roughly 89,000 business vials and 4,600 samples. Greater than 510,000 Syfovre injections, together with medical trials, are estimated to have been administered since launch by means of December 2024.
JP Morgan views Syfovre as an over $1.5 billion peak potential drug, even with conservative assumptions.
“Total, physicians proceed to make use of the product, driving development, and we anticipate a elementary and sentiment shift driving upside in APLS shares,” the analyst writes.
Analyst Rama additionally expects that the Empaveli C3 glomerulopathy and first immune advanced glomerulonephritis (C3G/IC-MPGN) alternative will probably be a driver for Apellis inventory. The corporate has submitted a supplemental advertising and marketing utility for approval of Empaveli primarily based on Part 3 VALIANT outcomes at six months; if accredited, a U.S. launch is predicted in 2H 2025.
Value Motion: APLS inventory is up 3.27% at $25.87 on the final verify Wednesday.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
